CLIMB: using scans and tissue biomarkers to learn more about primary CNS lymphoma
A Prospective Imaging and Translational Tissue Study in CNS Lymphoma to Enable Further Disease Characterisation and the Development of Potential Predictive and Prognostic Biomarkers
This project will try to use brain scans and tumour tissue from adults with newly diagnosed primary CNS lymphoma to find markers that predict treatment response and time without disease progression.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 36 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Royal Marsden NHS Foundation Trust Academic / other |
| Locations | 1 site (Sutton) |
| Trial ID | NCT05828628 on ClinicalTrials.gov |
What this trial studies
CLIMB is a single-centre prospective imaging and translational tissue programme run at The Royal Marsden. It will recruit adults with newly diagnosed primary CNS lymphoma who have not yet received CNS-directed therapy. Participants will provide tumour tissue for molecular analysis and undergo standardized imaging with response assessments using CCA to correlate imaging and molecular findings with progression-free survival. The study aims to identify candidate predictive and prognostic biomarkers that could guide future trials and clinical decision-making.
Who should consider this trial
Good fit: Adults (≥18 years) with a radiological or histological diagnosis of primary CNS lymphoma who have not received prior CNS-directed therapy (steroid use allowed) and who can consent or have an appropriate consultee/legal representative.
Not a fit: Patients with lymphoma outside the CNS are excluded and are unlikely to benefit from findings specific to primary CNS lymphoma, and those who have already had CNS-directed therapy are not eligible.
Why it matters
Potential benefit: If successful, the work could help doctors predict which patients are likely to respond to treatment and better estimate how long patients may remain progression-free.
How similar studies have performed: Previous research has suggested that imaging features and tissue biomarkers can be informative in CNS lymphoma, but validated predictive and prognostic markers remain limited, so this approach is exploratory.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Subjects capable of giving informed consent, or if appropriate, if subject's capacity is deemed limited due to CNS involvement, a consultee can provide consent on their behalf. Some patients with PCNSL may be incapable of providing their own consent due to the neurological effects of their disease. In these cases the patient will be classed as an incapacitated adult and a legal representative will be sought in accordance with English or Scottish law as applicable (see 7.2.1) * A radiological or histological diagnosis of primary CNS lymphoma. * Have not received prior CNS directed therapy. Prior use of steroids is permitted. * Participants aged ≥18 years old. Exclusion Criteria: \- Involvement of lymphoma outside of the CNS
Where this trial is running
Sutton
- The Royal Marsden NHS Foundation Trust, Downs Road — Sutton, United Kingdom (Recruiting)
Study contacts
- Principal investigator: Ian Chau — Royal Marsden NHS Foundation Trust
- Study coordinator: GI and Lymphoma Unit
- Email: GI.Trials@rmh.nhs.uk
- Phone: 02086426011
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.